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Context: Familial isolated pituitary adenoma (FIPA) due to aryl hydrocarbon receptor interacting protein (AIP)
genemutations is an autosomal dominant diseasewith incomplete penetrance. Clinical screeningof apparently
unaffected AIP mutation (AIPmut) carriers could identify previously unrecognized disease.
Objective:TodeterminetheAIPmutational statusofFIPAandyoungpituitaryadenomapatients, analyzingtheir clinical
characteristics, and to perform clinical screening of apparently unaffectedAIPmut carrier familymembers.
Design: This was an observational, longitudinal study conducted over 7 years.
Setting: International collaborative study conducted at referral centers for pituitary diseases.
Participants: FIPA families (n  216) and sporadic young-onset (30 y) pituitary adenoma patients (n  404)
participated in the study.
Interventions: We performed genetic screening of patients for AIPmuts, clinical assessment of their family
members, and genetic screening for somatic GNAS1 mutations and the germline FGFR4 p.G388R variant.
Main Outcome Measure(s): We assessed clinical disease in mutation carriers, comparison of characteristics of
AIPmut positive and negative patients, results of GNAS1, and FGFR4 analysis.
Results: Thirty-seven FIPA families and 34 sporadic patients hadAIPmuts. Patients with truncatingAIPmuts had
a younger age at disease onset and diagnosis, compared with patients with nontruncating AIPmuts. Somatic
GNAS1 mutations were absent in tumors from AIPmut-positive patients, and the studied FGFR4 variant did not
modify thediseasebehaviororpenetrance inAIPmut-positive individuals.A totalof164AIPmut-positiveunaffected
family members were identified; pituitary disease was detected in 18 of those who underwent clinical screening.
Conclusions: A quarter of the AIPmut carriers screened were diagnosed with pituitary disease, justifying this
screening and suggesting a variable clinical course for AIPmut-positive pituitary adenomas. (J Clin Endocrinol
Metab 100: E1242–E1254, 2015)
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Familial isolated pituitary adenoma (FIPA) is character-ized by the presence of pituitary adenomas in two or
more members of the same family in the absence of other
syndromic clinical features, such as those characteristic of
multiple endocrine neoplasia (MEN) type 1 and MEN4,
Carney complex or tumors related to mutations in the
succinate dehydrogenase genes. FIPA is a heterogeneous
condition, encompassing cases with unknown genetic
cause and patients with mutations in the aryl-hydrocar-
bon receptor interacting protein gene (AIP), with distinc-
tive clinical characteristics. GermlineAIPmutations (AIP-
muts) play a role not only in a subset of FIPA families (1–4)
but also in sporadically diagnosed pituitary adenomas (5–
9), and in the setting of somatostatin analog (SSA)-resis-
tant acromegaly (10). Another form of FIPA, X-linked
acrogigantism, due to microduplications in the Xq26.3
region, has been recently identified in patients with very
young-onset gigantism and pituitary adenoma/hyperpla-
sia (11).
The phenotype of AIPmut-associated pituitary adeno-
mas has been described before (2–4, 12), but a systematic
follow-up of cases and families is lacking due to the rela-
tive novelty of this pathogenic association (1), the variable
disease penetrance (4, 12–14), and the rarity of this clinical
entity. We present the clinical and genetic characteristics
of a large cohort of FIPA and simplex (patients with germ-
line mutation and no family history) AIPmut-positive pa-
tients, aiming for the following: 1) to perform a systematic
follow-up of families to identify and characterizeAIPmut-
positive carriers, 2) to seek the role of disease-modifying
genes on the variable phenotype and penetrance of the
disease, and 3) to confirm and extend the description of the
phenotype of AIPmut-positive patients, providing a com-
parison with AIPmut-negative cases. We establish that
genetic screening followed by clinical assessment identifies
a large percentage of family members with pituitary ab-
normalities, supporting the facilitation of genetic diagno-
sis and follow-up of these patients and their families.
Patients and Methods
Our study population (1725 subjects, Table 1) was re-
cruited via the collaborative research network of the In-
ternational FIPA Consortium (15). Pituitary adenoma pa-
tients were grouped into 11 clinical diagnostic categories
(Supplemental Table 1). The diagnoses of acromegaly, ac-
romegaly/prolactinoma, gigantism, gigantism/prolacti-
noma, and mild acromegaly (16) were grouped together
under the category of GH excess for some analyses.
Between January 2007 and January 2014, we recruited
patients from 35 countries from two different groups: ei-
ther members of FIPA families, defined by the presence of
pituitary adenomas in two or more members of a family
without other associated clinical features (1–3, 17) (fa-
milial cohort), or sporadically diagnosed pituitary ade-
noma patients with disease onset at 30 years of age or
younger (sporadic cohort). As an exception to these in-
clusion criteria, one AIPmut-positive sporadic patient
older than 30 years was found thanks to AIP screening in
Table 1. Study Population: Demographics and General Description
Familial Cohort Sporadic Cohort Combined
Total individuals, n, % 1231 (71.4) 494 (28.6) 1725 (100)
Females, n, % 668 (54.3) 250 (50.6) 918 (53.2)
Current age, median (range [IQR]) 46.2 (2–97 [32–62]) 35 (3–77 [26–42]) 42.6 (2–97 [29–56])
Clinical status, n, %
Affected 502 (40.8) 404 (81.8) 906 (52.5)
Unaffected 729 (59.2) 90 (18.2) 819 (47.5)
Affected males, n, % 219 (43.6) 203 (50.2) 422 (46.6)
Affected females, n, % 283 (56.4) 201 (49.8) 484 (53.4)
Diagnoses, n, %
Acromegaly 170 (33.9) 203 (50.2) 373 (41.2)
Acromegaly/prolactinoma 17 (3.4) 12 (3) 29 (3.2)
Cushing’s disease 24 (4.8) 21 (5.2) 45 (5)
FSHoma 2 (0.4) 1 (0.2) 3 (0.3)
Gigantism 44 (8.8) 65 (16.1) 109 (12)
Gigantism/prolactinoma 1 (0.2) 10 (2.5) 11 (1.2)
Mild acromegaly 2 (0.4) — 2 (0.2)
NFPA 91 (18.1) 21 (5.2) 112 (12.4)
Pituitary tumor 17 (3.4) 2 (0.5) 19 (2.1)
Prolactinoma 134 (26.7) 67 (16.6) 201 (22.2)
TSHoma — 2 (0.5) 2 (0.2)
GH excess patients, n, % 234 (46.6) 290 (71.8) 524 (57.8)
Abbreviations: FSHoma, FSH secreting adenoma. TSHoma, thyrotropinoma.
Dash indicates no patients in this category.
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the setting of a research study, and the screening of his
relatives detected a second AIPmut-positive pituitary ad-
enoma case; this family was included in the familial co-
hort. The first patient reported in each FIPA family and all
the sporadic patients were considered probands. All the
patients received treatment and were followed up in ac-
cordance with the guidelines and clinical criteria of their
respective centers. Relevant clinical and family structure
data were received from clinicians and/or patients, and
genetic screening was performed in the families of all the
AIPmut-positive probands, selecting individuals accord-
ing to their risk of inheriting the mutation, based on their
position in the family tree, and extending the screening to
as many generations as possible. In both familial and spo-
radic cases, other causes of familial pituitary adenomas,
such as MEN1 and MEN4, Carney complex, pheochro-
mocytoma/paraganglioma and pituitary adenoma syn-
drome, and X-linked acrogigantism were ruled out by clin-
ical, biochemical and, in some cases, genetic tests, as
appropriate.
The study population included a great majority of new
cases but also previously diagnosed patients being fol-
lowed up by the participating centers and a few historical
cases, corresponding to deceased members of FIPA fam-
ilies (further details in Supplemental Results). Four AIP-
mut-positive patients (two with diagnosis of acromegaly
and two with gigantism) died in the postrecruitment pe-
riod.Threeof thedeathsweredue tocardiovascular causes
(stroke, chronic heart failure, and acute coronary syn-
drome), whereas the exact cause of death is unknown in
the fourth, a patient with long-standing untreated familial
acromegaly.
All the patients and family members included agreed to
take part by providing signed informed consent forms ap-
proved by the local ethics committee. Further details on
the study population and the procedures for genetic/clin-
ical screening and search for disease-modifying genes are
described in the Supplemental Material.
Statistical analysis
The qualitative, categorical variables were expressed as per-
centages and compared using the2 test or the Fisher’s exact test,
as appropriate. The normal distribution of the quantitative vari-
ables was verified using the Shapiro-Wilk and the Kolmogorov-
Smirnov tests for normality. Means and SDs were used to report
parametric data, and nonparametric data were expressed as me-
dian and interquartile ranges. Parametric data were analyzed
with the unpaired t test, with a 95% confidence interval (CI),
whereas the Mann-Whitney U test was used for the nonpara-
metric data. Statistical significance was considered when the
P value was  .05. All the statistical analyses were carried out
using the GraphPad Prism 6 (GraphPad Software Inc) and Stata
12 (StataCorp LP) statistical software.
Results
Study population
The familial cohort was composed of 216 FIPA fami-
lies, including 156 new families (989 subjects: 337 patients
and 652 unaffected family members) and 60 previously
described families (3, 12), in which 46 new subjects (15
patients and 31 unaffected family members) were added to
the previously reported 196 individuals (150 patients and
46 unaffected family members). The sporadic cohort orig-
inally included 409 pituitary adenoma patients 30 years
old or younger at disease onset, with no known family
history of pituitary adenoma, but we excluded five pa-
tients from further analysis due to harboring an Xq26.3
microduplication. Of the remaining 404 sporadic pa-
tients, six were reported previously (3). In addition to the
AIPmut screening, a subset ofAIPmut-negative FIPA (n
55) and sporadic (n  45) patients underwent genetic
screening for other endocrine neoplasia-associated genes
(Supplemental Table 2). All of these tests were negative for
pathogenic variants. After the genetic screening and fol-
low-up of the patients and carriers, 60 individuals in the
familial cohort and seven in the sporadic cohort were
classified as not at risk of inheriting an AIPmut and
were excluded from further analysis. Twenty-three in-
dividuals initially thought to be unaffected were iden-
tified with pituitary abnormalities (see details in Pro-
spective diagnosis).
Genetic screening results
Thirty-seven of 216 FIPA families screened (17.1%)
and 34 of 404 sporadic patients (8.4%) were positive for
pathogenic or likely pathogenic AIPmuts, accounting for
a total of 71 AIPmut-positive kindreds and 144 AIPmut-
positive patients (76.4% familial and 23.6% simplex, Ta-
ble 2). We also identified 164AIPmut-positive apparently
unaffected family members (see Follow-up and prospec-
tive diagnosis). Samples were not available from family
members of 25AIPmut-positive simplex cases to establish
the presence or lack of de novo mutations. We identified
three pituitary adenoma patients (two with clinically non-
functioning pituitary adenoma [NFPA] and one with a
microprolactinoma) belonging to AIPmut-positive FIPA
families and being at risk of inheriting but not carrying an
AIPmut; therefore, they were considered as phenocopies.
Thirty-one different AIPmuts (10 not previously re-
ported) were identified in our study population: 12 exclu-
sively in familial cases, 12 in simplex cases only, and seven
in both settings (Table 3 and Supplemental Figure 1). Of
the total mutations, 70.8% (22/31) predicted a truncated
or missing protein and were termed as truncatingAIPmuts
(Supplemental Figure 2). We also identified 11 apparently
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nonpathogenic AIP variants (three of them novel) in our
population (Supplemental Table 3).
A multiple regression analysis was performed to deter-
mine which clinical features could more accurately predict
the likelihood of a patient to carry an AIPmut. An age at
diagnosis of 10 years or older and younger than 20 years
conferred an odds ratio (OR) of 5.8 (P  .000, 95% CI
3.1–10.8) of having an AIPmut, whereas the OR was 2.8
if the age at diagnosis was 20 years or older and younger
than 30 years (P .000, 95% CI 1.3–5.7); thus, an age at
diagnosis between 10 and 30 years is the best predictor of
AIPmuts. Inversely, a diagnosis of prolactinoma resulted
in an OR of 0.2 (P .000, 95% CI 0.1–0.5).
Genotype-phenotype correlation within the
AIPmut-positive cohort
Truncating mutations accounted for 78.9% of theAIP-
muts found in the familial cohort (15 of 19) and for 57.9%
of those detected in the sporadic cohort (11 of 19). To
study a possible difference in disease penetrance between
truncating and nontruncating mutations, we compared
the number of affected individuals with truncating AIP-
muts in the familial (85 of 110 [77.3%]) and simplex co-
horts (21 of 34 [61.8%]), finding no significant difference,
although a trend was observed (P  .0729, analysis in-
cluded prospectively diagnosed patients). No significant
differences were found regarding the proportion of GH
excess cases, number of patients per family, maximum
tumoral diameter, frequency of macroadenomas, extra-
sellar invasion, or number of treatments received between
the patients with truncating and nontruncating mutations.
However, patients with truncating mutations were signif-
icantly younger at disease onset (median 16 [interquartile
range (IQR) 15–25] vs 22 [IQR 17.3–27.8] y, P .0046,
Figure 1A) and at diagnosis (median 21 [IQR 16–30] vs 27
[IQR 20.8–37] y, P  .0028, Figure 1B), and the occur-
rence of pediatric cases was more common in this group
(60% [57 of 95], Figure 1C), compared with the patients
with nontruncating AIPmuts (33.3% [12 of 36], P 
.0064). In concordance with these differences, gigantism
accounted for a significantly higher proportion of the GH
excess cases in the patients with truncating AIPmuts
(54.7% [47 of 86]), compared with those with nontrun-
cating AIPmuts (30% [9 of 30], P  .0200). Because
p.R304* was the most commonAIPmut in our study pop-
Table 2. Screening for AIPmuts
Familial Cohort Sporadic Cohort Combined
AIPmut-
Positive
Familial
AIPmut-
Negative
Familial
Total
Familial
AIPmut-
Positive
Simplex
AIPmut-
Negative
Sporadic
Total
Sporadic
AIPmut-
Positive
Familial
and
Simplex
AIPmut-
Negative
Familial
and
Sporadic Total
Total number of kindreds, n, % 37 (17.1%
of
familial)
179 (82.9%
of
familial)
216 (34.8%
of total)
34 (8.4%
of
sporadic)
370 (91.6%
of
sporadic)
404 (65.2%
of total)
71 (11.5%
of total)
549 (88.5%
of total)
620 (100)
Total individuals, n, % 475 (38.6%
of
familial)
756 (61.4%
of
familial)
1231 (71.4%
of total)
82 (16.6%
of
sporadic)
412 (83.4%
of
sporadic)
494 (28.6%
of total)
557 (32.3%
of total)
1168 (67.7%
of total)
1725 (100)
Genetic status, n, %
AIPmut-negative patients 3 (0.6) 389 (51.5)a 392 (31.8) — 370 (89.8) 370 (74.9) 3 (0.5) 759 (65) 762 (44.2)
AIPmut-positive tested
patients
95 (20) — 95 (7.7) 34 (41.5) — 34 (6.9) 129 (23.2) — 129 (7.5)
At risk but not tested 33 (6.9) — 33 (2.7) 8 (9.8) — 8 (1.6) 41 (7.4) — 41 (2.4)
Not at risk 48 (10.1) 12 (1.6) 60 (4.9) 7 (8.5) — 7 (1.4) 55 (9.9) 12 (1) 67 (3.9)
Obligate unaffected carriers,
not tested
8 (1.7) — 8 (0.6) 2 (2.4) — 2 (0.4) 10 (1.8) — 10 (0.6)
Predicted AIPmut-positive
patients
15 (3.2) — 15 (1.2) — — — 15 (2.7) — 15 (0.9)
Unaffected AIPmut tested
carriers
120 (25.3) — 120 (9.7) 16 (19.5) — 16 (3.2) 136 (24.4) — 136 (7.9)
Unaffected and AIPmut
negative
153 (32.2) — 153 (12.4) 15 (18.3) — 15 (3) 168 (30.2) — 168 (9.7)
Unaffected relatives of
AIPmut-negative patients
— 355 (47) 355 (28.8) — 42 (10.2) 42 (8.5) — 397 (34) 397 (23)
Summary of AIPmut-positive individuals, n, %
Total AIPmut-positive
patientsb
110 (23.2) — 110 (8.9) 34 (41.5) — 34 (6.9) 144 (25.9) — 144 (8.3)
Total unaffected AIPmut
carriersc
128 (26.9) — 128 (10.4) 18 (22) — 18 (3.6) 146 (26.2) — 146 (8.5)
Dash indicates no individuals in this category.
a In AIPmut-negative FIPA families, 199 patients were tested for AIPmuts; the rest (n  190) were assumed to be negative.
b This is equal to the sum of tested AIPmut-positive patients plus the predicted AIPmut-positive patients.
c Sum of tested unaffected carriers plus obligate unaffected carriers.
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ulation (20 kindreds), we analyzed whether these patients
behaved differently from other patients with truncating
mutations. We found more affected individuals per family
(median 4 [IQR 2.5–5]) among families carrying the
p.R304* AIPmut, compared with families with other
AIPmuts (median 2 [IQR 2–3], P  .0133). When con-
Table 3. AIP Pathogenic or Likely Pathogenic Mutations in the Familial and Sporadic Cohorts
Mutation (DNA Level
[Protein Level]) Mutation Type Pathogenic
Location in
Protein
Familial
Cohort
(n  238)a
Simplex
Cohort
(n  52)a
Combined
(n  290)a References/SRb
g.4856_4857CGAA Promoter Yesc Not in protein (5
UTR)
3 (1.3) — 3 (1) (3, 12)/(SR30)
c.3GA (p.?) Start codon Likelyc N terminus 2 (0.8) — 2 (0.7) This paper
c.40CT (p.Q14*) Nonsense Yesc N terminus 2 (0.8) — 2 (0.7) (1)/(SR31, 32)
c.70GT (p.E24*) Nonsense Yesc N terminus 9 (3.8) — 9 (3.1) (3)/(SR33)
c.74_81delins7 (p.L25Pfs*130) Frameshift Yesc PPIase domain 10 (4.2) — 10 (3.4) (12)/(SR34)
c.100–1025_279  357del
(ex2del) (p.A34_K93del)
Large genomic
deletion
Yesc PPIase domain 12 (5) 2 (4) 14 (4.8) (SR35)
c.100–18CT Intronic Likely Not in
protein (intron
1)
— 3 (6) 3 (1) (3, 7, 10)/(SR31)
c.241CT (p.R81*) Nonsense Yesc PPIase domain 12 (5) 4 (8) 16 (5.5) (3)/(SR30, 36–38)
c.249GT (p.G83Afs*15) Splice site (cryptic
splice site)
Yesc PPIase domain 4 (1.7) — 4 (1.4) (12)
c.338_341dup (p.L115Pfs*16) Frameshift Yesc PPIase domain — 2 (4) 2 (0.7) (6)
c.427CT (p.Q143*) Nonsense Yesc Between PPIase
and TPR1
domains
— 1 (2) 1 (0.3) This paper
c.469–2AG (p.E158_Q184del) Splice site Likely TPR1 domain — 1 (2) 1 (0.3) (5)/(SR39, 40)
c.490CT (p.Q164*) Nonsense Yesc Between PPIase
and TPR1
domains
3 (1.3) — 3 (1) (12)
c.570CG (p.Y190*) Nonsense Yesc TPR1 domain 9 (3.8) — 9 (3.1) This paper
c.662dupC (p.E222*) Nonsense Yesc Between TPR1
and 2 domains
3 (1.3) — 3 (1) (12)
c.713GA (p.C238Y) Missense Yes TPR2 domain 4 (1.7) — 4 (1.4) (3)/(SR33)
c.783CG (p.Y261*) Nonsense Yesc TPR2 domain 4 (1.7) — 4 (1.4) (9)/(SR39, 41, 42)
c.787  9CT Intronic Uncertain Not in
protein (intron
5)
— 1 (2) 1 (0.3) This paper
c.804CA (p.Y268*) Nonsense Yesc TPR3 domain 19 (8) 3 (6) 22 (7.6) (SR43, 44)
c.805_825dup
(p.F269_H275dup)
In-frame insertion Yes TPR3 domain 16 (6.7) 2 (4) 18 (6.2) (3)/(SR30, 39, 45)
c.807CT (p.()) Splice site
(reduced
transcript level)
Yes TPR3 domain 7 (2.9) 4 (8) 11 (3.8) (3, 5, 7, 10, 12)/
(SR46, 47)
c.811CT (p.R271W) Missense Yes TPR3 domain — 1 (2) 1 (0.3) (2, 7, 12)/(SR48)
c.816delC (p.K273Rfs*30) Frameshift Yesc TPR3 domain — 1 (2) 1 (0.3) This paper
c.868AT (p.K290*) Nonsense Yesc TPR3 domain — 1 (2) 1 (0.3) This paper
c.872_877delTGCTGG
(p.V291_L292del)
In-frame deletion Yes TPR3 domain — 1 (2) 1 (0.3) This paper
c.910CT (p.R304*) Nonsense Yesc C-terminal -
helix
88 (37) 16 (31) 104 (35.9) (1–3, 5, 7, 9, 12,
14)/ (SR39, 49–
51)
c.911GA (p.R304Q) Missense Yes C-terminal -
helix
20 (8.4) 3 (6) 23 (7.9) (3, 5, 7, 9, 12)/
(SR31, 39, 52,
53)
c.967delC (p.R323Gfs*39) Frameshift Yesc C-terminal -
helix
— 4 (8) 4 (1.4) This paper
c.976_977insC (p.G326Afs*?) Frameshift Yesc C-terminal -
helix
— 1 (2) 1 (0.3) This paper
c.978dupG (p.I327Dfs*?) Frameshift Yesc C-terminal -
helix
— 1 (2) 1 (0.3) This paper
c.1-?_993?del (whole gene
deletion)
Large genomic
deletion
Yesc Absence of the
whole protein
11 (4.6) — 11 (3.8) (12)
Abbreviations: PPIase, peptidylprolyl isomerase; SR, supplemental references; TPR, tetratricopeptide repeat; UTR, untranslated region.
Dash indicates no individuals in this category.
a Number of positive individuals for each mutation, considering the AIPmut-positive tested individuals, the obligate carriers, and the predicted
AIPmut patients.
b For supplemental references, see Supplemental Material.
c Truncating mutation.
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sidering all theAIPmut-positive patients together (familial
and sporadic), we found a higher proportion of pediatric
patients among those with the AIP p.R304* mutation
(65.8% [25 of 38] vs 46.5% [40 of 86], P  .0475).
Clinical and histopathological features
Findings regarding gender distribution, age at onset/
diagnosis, distribution of clinical diagnoses, tumor size/
extension, pituitary apoplexy, histopathological features,
extrapituitary tumors, and specific analyses of patients
with GH excess and with gigantism are detailed in the
Supplemental Material and depicted in Supplemental Ta-
bles 4 and 5 and Supplemental Figures 3–7.
Disease penetrance
To calculate the penetrance of pituitary adenomas
among AIPmut positive families, complete data are
needed both for phenotype and genotype. Therefore, we
have selected three families (two with p.R304* and one
with p.A34_K39del mutations) in which complete data
were available in three or more generations for consenting
at-risk individuals. The AIP genotype was known in
76.6% (range 68.4%–94.7%) of the individuals at risk; of
them, 16.8% were patients and 83.2% were unaffected
carriers. The gender distribution was similar between pa-
tients and unaffected carriers. The
mean penetrance in these three fam-
ilies was 28.6% (19%–38.1%), and
it decreased to 22.7% (18.2%–
26.7%) when 50% of the individu-
als at risk with unknown genotype
were considered as unaffected car-
riers. When the prospectively diag-
nosed patients were omitted from
this calculation, the total pen-
etrance of pituitary adenomas was
12.5%, highlighting the impor-
tance of the follow-up of appar-
ently unaffected carriers for the
correct calculation of the disease
penetrance.
Because penetrance cannot be ap-
propriately calculated for AIPmut-
negative families, we assessed the
number of affected family members.
The AIPmut-positive families had
more affected individuals per family
than the AIPmut-negative families
(P  .0001, Supplemental Figure
7E). Whereas 84.9% of theAIPmut-
negative families (152 of 179) had
only two affected members, 48.6%
of the AIPmut-positive families (18
of 37) had three or more pituitary adenoma patients per
family. The maximum number of affected individuals
within the same family was eight (six of them prospectively
diagnosed) in a family carrying the p.R304*AIPmut, and
the maximum number of cases of gigantism in the same
family was five, in a FIPA family with the p.E24*AIPmut.
Follow-up and prospective diagnosis
Of the 164 originally identified AIPmut carriers, 160
were available and advised to undergo biochemical and
clinical screening. Prospective diagnosis of a pituitary ad-
enoma was established in 11.3% (18 subjects, 11 males) of
the individuals originally considered as unaffected AIP-
mut carriers.
Six of the prospectively diagnosed patients had acro-
megaly (one of them with prolactin [PRL] cosecretion),
one patient had gigantism, two patients were diagnosed
with mild acromegaly (16), and nine patients harbored
NFPAs. Of the 142 individuals remaining as apparently
unaffected AIPmut carriers, 79 (55.6%) underwent clin-
ical assessment and one or more biochemical or imaging
tests, whereas 63 subjects (44.4%) had only clinical
evaluation.
Figure 1. Patients with truncating vs nontruncating AIPmuts. Patients with truncating AIPmuts
present with a more aggressive phenotype, characterized by an earlier age at onset (A) (P 
.005) and (B) at diagnosis (P  .003). C, This earlier disease onset results in a higher frequency of
pediatric cases (n [total]  131); in fact, most of the patients with truncating mutations present
in childhood and adolescence. **, P  .01.
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The prospective cases were diagnosed at an older age
than the rest of the patients (median 30 [IQR 22.8–39.5]
vs 23 [IQR 16–33] y, P .025). At diagnosis, seven of the
prospectively diagnosed patients were symptomatic
(headaches, arthralgias, acral growth, facial changes,
weight gain, or hyperhidrosis). Five of the 18 prospectively
diagnosed tumors were macroadenomas, in contrast with
a predominance of macroadenomas (89.9%, 71 of 79) in
the rest of theAIPmut-positive FIPA patients (P .0001).
The maximum diameter was significantly smaller for pro-
spective cases (median 5.8 [IQR 4.7–14.4] vs 16.5 [IQR
10–29] mm, P  .0002). Four of the patients with mac-
roadenomas had surgery, and the histopathological study
confirmed GH- or GH/PRL-positive adenomas. The fifth
macroadenoma was identified in a 68-year-old male pa-
tient with high IGF-1, well-controlled hypertension and
diabetes mellitus and no other comorbidities or symp-
toms, who did not want to receive any treatment. In ad-
dition, one AIPmut-negative pituitary adenoma patient,
harboring a 25-mm NFPA, was prospectively diagnosed
as part of an AIPmut-positive family (brother of the AIP-
mut positive proband).
A further seven subjects had abnormalities in their
screening tests, but a pituitary disease was not confirmed:
five individuals had slightly elevated IGF-1 levels for their
age/gender, one patient displayed acromegaloid features
but normal pituitary magnetic resonance imaging (MRI)
and biochemistry, and a 17-year-old female had repeat-
edly borderline high IGF-1 and incompletely suppressed
GH on oral glucose tolerance test, but her bulky pituitary
gland (11 mm in height), normal at this age group, is not
changing during follow-up and her biochemical results are
now within the normal range, after 3 years of follow-up.
The global penetrance of pituitary adenomas among
the individuals initially considered as unaffected AIPmut
carriers was 11.3% (18 of 160). However, the penetrance
was higher in the group of carriers who underwent bio-
chemical and imaging investigations, varying between
18.6% and 28.1%, depending on the depth of screening
(Figure 2). Overall, these data suggest that approximately
20%–25% of the apparently unaffected AIPmut carriers
screened with biochemical or imaging tests will be iden-
tified with a pituitary adenoma at some point in their lives.
Clinical screening was not systematically performed in
the AIPmut-negative FIPA unaffected family members.
Nevertheless, due to the increased disease awareness given
by the existence of previous pituitary adenoma cases
within their families, four individuals (three females and
one male) from three different AIPmut-negative FIPA
families were prospectively diagnosed. Three of them har-
bored NFPAs, but we lack complete information about the
fourth patient. The mean age at diagnosis in the three
NFPA cases was 37 years, and only one patient referred
symptoms at diagnosis (galactorrhea, not clearly associ-
ated to stalk compression, and lethargy). All of them had
microadenomas, with a mean diameter of 6.5 mm and did
not require any therapeutic intervention other than hor-
monal replacement in one case. The characteristics of
these cases resemble those of incidentalomas; however, the
occurrence of two prospective cases in the same family
supports an apparent inherited component.
Disease-modifying genes
We have studied the role of two possible disease-mod-
ifying genes: GNAS1 (somatic) (18) and FGFR4 (germ-
line) (19).GNAS1mutations were absent in all the studied
AIPmut-positive somatotropinomas (n  23) but were
detected in 50% of the AIPmut-negative familial soma-
totropinomas (5 of 10), 16.7% of the AIPmut-negative,
young-onset cases (1 of 6), and 26.3% of the unselected
acromegaly cases studied (5 of 19). The distribution of the
FGFR4 p.G388R single-nucleotide polymorphism (SNP)
conserved the Hardy-Weinberg equilibrium (20), and the
genotype distribution was similar between patients (n 
98) and AIPmut carriers (n 108) (P .523). The age at
onset and at diagnosis, tumor size, and frequency of ex-
trasellar invasion were not significantly different between
the GG (wild type) and GR/RR patients.
Discussion
AIPmuts are prevalent in young-onset, GH excess patients
(24%) and FIPA (17.1%), with more than double fre-
quency in patients with gigantism (46.7%) in our cohort,
Figure 2. Penetrance in screened AIPmut-positive carriers (n [total] 
160). The probability of detecting new cases of pituitary adenomas
within apparently unaffected AIPmut carriers depends on the clinical
assessment and the type of complementary biochemical/imaging
studies included in the screening protocol (see text).
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in concordance with other studies (7, 9, 21, 22). However,
in contrast to previous reports, in this large and exten-
sively studied cohort, there was no predominance of male
patients among the AIPmut-positive familial cases, and
equal numbers of male and female unaffected carriers
were identified. Earlier studies (3, 4, 12, 23) may have had
an ascertainment bias for families with cases of gigantism,
a disease that is more prevalent in males, at least partly due
to the physiologically later puberty and therefore later
cessation of growth in boys.
We have demonstrated that approximately a quarter of
the individuals initially identified as unaffected AIPmut
carriers who underwent clinical screening tests were di-
agnosed with pituitary abnormalities. Full clinical screen-
ing identified 28.1% of the carriers, with fewer tests un-
derstandably resulting in fewer positive cases. Our data
suggest that not all the AIPmut-associated pituitary ade-
nomas have a rapidly growing, aggressive phenotype. The
follow-up of these patients allowed us to observe some
probably very early cases of acromegaly, in which the cur-
rent clinical scenario had not indicated intervention at
data closure. We cannot rule out that some of the small
NFPAs are indeed incidentalomas, similar to those fre-
quently observed in AIPmut-negative subjects of the gen-
eral population.
This frequency of prospective diagnosis may justify the
clinical screening and, possibly, follow-up of all the AIP-
mut-positive unaffected carriers. Our data would support
the assessment of all the newly identified AIPmut carriers
(clinical examination/history, PRL, and IGF-1, as a min-
imum, up to a full screening, also including an oral glucose
tolerance test and contrast enhanced pituitary MRI). Fol-
low-up of the younger family members should continue
until at least 30 years of age, preferably annually, with
clinical assessment and basal pituitary hormonal levels,
leaving stimulation tests for cases with suspicion of pitu-
itary disease and a follow-up MRI if necessary (24, 25).
The cost-effectiveness and the possible psychological bur-
den of this approach will need future study. Stopping the
follow-up should be considered in older patients, given the
low possibility of detecting new pituitary adenoma pa-
tients in these individuals after the fifth decade of life (24,
25). Once a case has been prospectively diagnosed, the
treatment and follow-up should proceed as for the general
population of pituitary adenoma patients because there
are no data to suggest a different type of treatment in
AIPmut-positive patients (26) although reduced SSA re-
sponsiveness has been described.
The genetic and clinical screening of AIPmut-negative
FIPA families is uncertain at this point. Baseline screening
and follow-up of obligate carriers could be considered,
keeping in mind that the age of onset is considerably older
in these families. Education on possible signs and symp-
toms of family members is a viable option in the routine
setting. We expect that the identification of further genes
implicated in the pathogenesis of FIPA in the next years
will allow us to tailor these recommendations in accor-
dance with the clinical behavior of each genetic entity.
Patients with GH excess starting before the age of 5
years should be tested for the recently identified Xq26.3
chromosomal microduplications (11). The genetic screen-
ing of other sporadic, young-onset pituitary adenoma pa-
tients with no evidence of other endocrine tumors should
be focused on AIPmuts in first instance in cases of GH
excess (with or without PRL cosecretion) and on MEN1
mutations, especially in cases of prolactinoma (9) because
this can be the first manifestation of MEN1 (27). Whether
it would be advisable to continue screening young patients
with other diagnoses for AIPmuts out of the setting of
research studies needs longer follow-up.
To explain the variable clinical phenotype in our AIP-
mut-positive patients, we evaluated the possible influence
of two disease-modifying genes, GNAS1 and FGFR4.
Whereas somatic GNAS1 mutations are common in un-
selected somatotropinomas (4.4%–59% of the cases)
(28–35), we have not identified any in adenomas from
AIPmut-positive patients, suggesting that germline AIP-
muts and somatic GNAS1 mutations are mutually exclu-
sive in somatotropinomas.GNAS1mutations have rarely
been studied in pediatric patients with acromegaly and
gigantism, and they seem to be an extremely infrequent
finding in this age group (36, 37). A recent study has
shown no change in the AIP immunostaining in sporadic
somatotropinomas in the presence of GNAS1 mutations
(38). The characteristic phenotype of adenomas contain-
ing the GNAS1 mutations (small [32, 39], highly respon-
sive to the treatment with SSAs, and more often densely
granulated according to some [40], but not all studies
[41]), seems to be in contrast with the typical AIPmut-
positive tumor phenotype. On the other hand, in soma-
totroph adenomas of AIPmut-negative FIPA patients,
half of the tested samples had GNAS1 mutations. This
suggests that in AIPmut-negative FIPA, the somatic
GNAS1 mutations could exist in a similar frequency as
in unselected somatotropinomas and possibly, in addi-
tion to a germline predisposing mutation, may play a
role in their pathogenesis.
The FGFR4 gene SNP rs351855 (c.1162GA,
p.G388R), with a minor allele frequency of 0.3, is a pre-
dictor of progression and poor prognosis in a variety of
human neoplasms (42). A role for rs351855 as a facilitator
of somatotroph cell tumorigenesis has been recently pro-
posed (19), and we hypothesized that this variant could
increase the penetrance and/or size and extension of AIP-
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mut-positive pituitary adenomas. The screening for this
SNP in our AIPmut-positive patients failed to show in-
crease in size, extension, or apoplexy, even though this
association had previously been suggested in sporadic
acromegaly patients (19), and no earlier onset or higher
penetrance was observed. The lack of association with
these two potentially disease-modifying genes suggests
that AIPmut-related pituitary adenomas are regulated
by different pathogenic mechanisms than unselected
somatotropinomas.
We recognize the numerous limitations of our study.
We chose an arbitrary age cutoff (30 y), in concordance
with previousAIP-related publications, but our data show
that only 13.2% of the AIPmut-positive patients had dis-
ease onset after the age of 30 years. Our patients were
recruited from different genetic backgrounds, and this
could have influenced the disease penetrance and presen-
tation. On the other hand, 19.7% of the AIPmut-positive
kindreds (24.3% of the AIPmut positive patients) belong
to a cohort with a founder AIPmut (p.R304*), originally
from Northern Ireland (14). The larger number of subjects
screened in these families provided a higher number of
carriers and chance for detection of affected individuals.
Additional genetic traits possibly cosegregating with this
founder mutation could modify the phenotype and thus
introduce a bias into our results. Full genotype and phe-
notype data were not available for all the families; there-
fore, we limited our penetrance calculations to three large,
well-characterized families. A better assessment of the
prevalence of pituitary apoplexy and extrapituitary ade-
nomas in AIPmut-positive patients would require a large
control group, screened ad hoc, which was beyond the
scope of this study. Finally, the data about therapeutic
modalities were limited, hampering the analysis of the re-
sponse to different treatments.
Conclusions
The analysis of this large cohort of FIPA patients allowed
us to establish a number of novel aspects of FIPA. A phe-
notype-genotype correlation was found with younger on-
set of disease in patients with truncating AIPmuts. We
identified a surprisingly high percentage of somatic
GNAS1 mutations in the AIPmut-negative somatotropi-
nomas and their absence in AIPmut-positive tumors. The
lack of influence of the germline FGFR4 p.G388R variant
on disease penetrance/severity suggests that currently un-
known factors drive penetrance and variable phenotype in
AIPmut-positive pituitary adenomas. The presence of
milder, more indolent disease in some AIPmut-positive
subjects has been established. Genetic and clinical screen-
ing leads to the prospective identification of an unexpect-
edly high proportion of affected patients in the originally
apparently unaffected carrier group, resulting in earlier
diagnosis and treatment and, possibly, better long-term
outcome (25). The recruitment of a large study population
with this uncommon disease has only been possible thanks
to worldwide collaboration.
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